Manganese-based MRI contrast agents: Past, present, and future

Dipanjan Pan; Anne H. Schmieder; Samuel A. Wickline; Gregory M. Lanza

doi:10.1016/j.tet.2011.07.076

Manganese-based MRI contrast agents: Past, present, and future

Dipanjan Pan, Anne H. Schmieder, Samuel A. Wickline, Gregory M. Lanza

Research output: Contribution to journal › Review article › peer-review

Original language	English
Pages (from-to)	8431-8444
Number of pages	14
Journal	Tetrahedron
Volume	67
Issue number	44
DOIs	https://doi.org/10.1016/j.tet.2011.07.076
State	Published - Nov 4 2011

Access to Document

10.1016/j.tet.2011.07.076

Cite this

@article{3c8968fe1ded41d08ade72b80717dbf5,

title = "Manganese-based MRI contrast agents: Past, present, and future",

author = "Dipanjan Pan and Schmieder, {Anne H.} and Wickline, {Samuel A.} and Lanza, {Gregory M.}",

note = "Funding Information: Dr. Dipanjan Pan is Assistant Professor of Medicine at the Division of Cardiology, Washington University in St. Louis with over 50 original publications, numerous abstracts, and patents in the area of materials science, chemistry, and nanotechnology. He received his Ph.D. in Synthetic Chemistry from the Indian Institute of Technology, Kharagpur, India in 2002 and pursued a post-doctoral career in polymer science and technology at the Department of Chemistry, Washington University in St. Louis. In 2005, he joined General Electric and worked as a part of the global research team toward the development of their biosciences initiatives. Dr. Pan joined the WU faculty in 2007. Subsequently, he co-invented several nanoparticle platforms for molecular imaging application with CT, MRI, optical, and photoacoustic imaging. His research is broadly aimed at the understanding and developing novel lipid-based and polymeric nanoparticle platforms for molecular imaging, drug delivery, and non-viral gene delivery applications with a focus on structure, function, and engineering processes. His multidisciplinary approaches encompass a variety of chemical, polymeric, molecular biological, and analytical methods to address issues related to cardiovascular and cancer diseases. His research is funded externally by National Institute of Health (NIH), American Heart Association (AHA), Missouri Life Sciences etc. He is presently a principal investigator in two AHA funded projects and a co-PI in a NIH research grant. He is a research member of the Siteman Cancer Center and presently serves as the editorial board member of the Journal of Biotechnology and Biomaterials (OMICS) and World Journal of Radiology (Baishideng Publishing). Funding Information: The financial support from the AHA 0835426N , 11IRG5690011 , NIH under the Grants NS059302 , CA119342 , HL073646 , CA1547371 , NS073457 and the NCI under the Grant N01CO37007 is greatly appreciated. ",

year = "2011",

month = nov,

day = "4",

doi = "10.1016/j.tet.2011.07.076",

language = "English",

volume = "67",

pages = "8431--8444",

journal = "Tetrahedron",

issn = "0040-4020",

number = "44",

}

TY - JOUR

T1 - Manganese-based MRI contrast agents

T2 - Past, present, and future

AU - Pan, Dipanjan

AU - Schmieder, Anne H.

AU - Wickline, Samuel A.

AU - Lanza, Gregory M.

N1 - Funding Information: Dr. Dipanjan Pan is Assistant Professor of Medicine at the Division of Cardiology, Washington University in St. Louis with over 50 original publications, numerous abstracts, and patents in the area of materials science, chemistry, and nanotechnology. He received his Ph.D. in Synthetic Chemistry from the Indian Institute of Technology, Kharagpur, India in 2002 and pursued a post-doctoral career in polymer science and technology at the Department of Chemistry, Washington University in St. Louis. In 2005, he joined General Electric and worked as a part of the global research team toward the development of their biosciences initiatives. Dr. Pan joined the WU faculty in 2007. Subsequently, he co-invented several nanoparticle platforms for molecular imaging application with CT, MRI, optical, and photoacoustic imaging. His research is broadly aimed at the understanding and developing novel lipid-based and polymeric nanoparticle platforms for molecular imaging, drug delivery, and non-viral gene delivery applications with a focus on structure, function, and engineering processes. His multidisciplinary approaches encompass a variety of chemical, polymeric, molecular biological, and analytical methods to address issues related to cardiovascular and cancer diseases. His research is funded externally by National Institute of Health (NIH), American Heart Association (AHA), Missouri Life Sciences etc. He is presently a principal investigator in two AHA funded projects and a co-PI in a NIH research grant. He is a research member of the Siteman Cancer Center and presently serves as the editorial board member of the Journal of Biotechnology and Biomaterials (OMICS) and World Journal of Radiology (Baishideng Publishing). Funding Information: The financial support from the AHA 0835426N , 11IRG5690011 , NIH under the Grants NS059302 , CA119342 , HL073646 , CA1547371 , NS073457 and the NCI under the Grant N01CO37007 is greatly appreciated.

PY - 2011/11/4

Y1 - 2011/11/4

UR - http://www.scopus.com/inward/record.url?scp=80053278341&partnerID=8YFLogxK

U2 - 10.1016/j.tet.2011.07.076

DO - 10.1016/j.tet.2011.07.076

M3 - Review article

C2 - 22043109

AN - SCOPUS:80053278341

SN - 0040-4020

VL - 67

SP - 8431

EP - 8444

JO - Tetrahedron

JF - Tetrahedron

IS - 44

ER -

Manganese-based MRI contrast agents: Past, present, and future

Access to Document

Other files and links

Cite this